420 related articles for article (PubMed ID: 28283856)
21. Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosis.
Surber MW; Beck S; Pham S; Marsden AT; Gandi SK; Baily J; McElroy MC
Pulm Pharmacol Ther; 2020 Aug; 63():101938. PubMed ID: 32841676
[TBL] [Abstract][Full Text] [Related]
22. Precision-cut lung slices from bleomycin treated animals as a model for testing potential therapies for idiopathic pulmonary fibrosis.
Cedilak M; Banjanac M; Belamarić D; Paravić Radičević A; Faraho I; Ilić K; Čužić S; Glojnarić I; Eraković Haber V; Bosnar M
Pulm Pharmacol Ther; 2019 Apr; 55():75-83. PubMed ID: 30776489
[TBL] [Abstract][Full Text] [Related]
23. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
24. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
25. The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models.
Kim YS; Cha H; Kim HJ; Cho JM; Kim HR
Molecules; 2019 Jul; 24(15):. PubMed ID: 31370295
[TBL] [Abstract][Full Text] [Related]
26. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
[TBL] [Abstract][Full Text] [Related]
27. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
Rodríguez-Portal JA
Drugs R D; 2018 Mar; 18(1):19-25. PubMed ID: 29209910
[TBL] [Abstract][Full Text] [Related]
29. Nintedanib in the treatment of idiopathic pulmonary fibrosis.
Mazzei ME; Richeldi L; Collard HR
Ther Adv Respir Dis; 2015 Jun; 9(3):121-9. PubMed ID: 25862013
[TBL] [Abstract][Full Text] [Related]
30. Nintedanib Inhibits Endothelial Mesenchymal Transition in Bleomycin-Induced Pulmonary Fibrosis via Focal Adhesion Kinase Activity Reduction.
Yu WK; Chen WC; Su VY; Shen HC; Wu HH; Chen H; Yang KY
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897764
[TBL] [Abstract][Full Text] [Related]
31. Improvement in Patient-Reported Outcomes and Forced Vital Capacity during Nintedanib Treatment of Idiopathic Pulmonary Fibrosis.
Takeda T; Takeuchi M; Saitoh M; Takeda S
Tohoku J Exp Med; 2018 Jun; 245(2):107-114. PubMed ID: 29925700
[TBL] [Abstract][Full Text] [Related]
32. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
Wongkarnjana A; Yanagihara T; Kolb MR
Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
[No Abstract] [Full Text] [Related]
33. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
[TBL] [Abstract][Full Text] [Related]
34. Nintedanib-mediated improvement in CT imaging in pulmonary fibrosis associated with systemic scleroderma.
Nishino K; Sasatani Y; Ohara G; Kagohashi K; Satoh H
Adv Respir Med; 2021; 89(5):528-531. PubMed ID: 34569613
[TBL] [Abstract][Full Text] [Related]
35. Human microvasculature-on-a chip: anti-neovasculogenic effect of nintedanib in vitro.
Zeinali S; Bichsel CA; Hobi N; Funke M; Marti TM; Schmid RA; Guenat OT; Geiser T
Angiogenesis; 2018 Nov; 21(4):861-871. PubMed ID: 29967964
[TBL] [Abstract][Full Text] [Related]
36. Fluorofenidone attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice via restoring caveolin 1 expression and inhibiting mitogen-activated protein kinase signaling pathway.
Meng J; Zou Y; Hu C; Zhu Y; Peng Z; Hu G; Wang Z; Tao L
Shock; 2012 Nov; 38(5):567-73. PubMed ID: 23042199
[TBL] [Abstract][Full Text] [Related]
37. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
38. Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis.
Senoo S; Miyahara N; Taniguchi A; Oda N; Itano J; Higo H; Hara N; Watanabe H; Kano H; Suwaki T; Fuchimoto Y; Kajimoto K; Ichikawa H; Kudo K; Shibayama T; Tanimoto Y; Kuyama S; Kanehiro A; Maeda Y; Kiura K;
PLoS One; 2020; 15(8):e0236935. PubMed ID: 32853277
[TBL] [Abstract][Full Text] [Related]
39. Nintedanib modulates type III collagen turnover in viable precision-cut lung slices from bleomycin-treated rats and patients with pulmonary fibrosis.
Hesse C; Beneke V; Konzok S; Diefenbach C; Bülow Sand JM; Rønnow SR; Karsdal MA; Jonigk D; Sewald K; Braun A; Leeming DJ; Wollin L
Respir Res; 2022 Aug; 23(1):201. PubMed ID: 35927669
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
